Cargando…
Radiotherapy and Chemotherapy Features in the Treatment for Locoregional Recurrence of Endometrial Cancer: A Systematic Review
Radiation therapy (RT) is the standard of care in patients with locoregional or isolated vaginal recurrence who never underwent irradiation. It is often associated with brachytherapy (BT), whereas chemotherapy (CT) is a rare treatment option. We systematically searched the PubMed and Scopus database...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10304022/ https://www.ncbi.nlm.nih.gov/pubmed/37373875 http://dx.doi.org/10.3390/jpm13060886 |
_version_ | 1785065410495774720 |
---|---|
author | Ronsini, Carlo Iavarone, Irene Reino, Antonella Vastarella, Maria Giovanna De Franciscis, Pasquale Sangiovanni, Angelo Della Corte, Luigi |
author_facet | Ronsini, Carlo Iavarone, Irene Reino, Antonella Vastarella, Maria Giovanna De Franciscis, Pasquale Sangiovanni, Angelo Della Corte, Luigi |
author_sort | Ronsini, Carlo |
collection | PubMed |
description | Radiation therapy (RT) is the standard of care in patients with locoregional or isolated vaginal recurrence who never underwent irradiation. It is often associated with brachytherapy (BT), whereas chemotherapy (CT) is a rare treatment option. We systematically searched the PubMed and Scopus databases in February 2023. We included patients with relapsed endometrial cancer, describing the treatment of locoregional recurrence, and reporting at least one outcome of interest—disease-free survival (DFS), overall survival (OS), recurrence rate (RR), site of recurrence, and major complications. A total of 15 studies fulfilled the inclusion criteria. Overall, 11 evaluated RT only, 3 evaluated CT, and 1 analyzed oncological outcomes after administration with a combination of CT and RT. In total, 4.5-year OS ranged from 16% to 96%, and DFS ranged from 36.3% to 100% at 4.5 years. RR ranged from 3.7% to 98.2% during a median follow-up of 51.5 months. Overall, RT showed a 4.5-year DFS from 40% to 100%. CT revealed 36.3% DFS at 4.5 years. RT showed a 4.5-year OS ranging from 16% to 96%, whereas CT revealed a 27.7% OS rate. It would be appropriate to test multi-modality regimens to evaluate outcomes and toxicity. EBRT and BT are the most employed options to treat vaginal recurrences. |
format | Online Article Text |
id | pubmed-10304022 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103040222023-06-29 Radiotherapy and Chemotherapy Features in the Treatment for Locoregional Recurrence of Endometrial Cancer: A Systematic Review Ronsini, Carlo Iavarone, Irene Reino, Antonella Vastarella, Maria Giovanna De Franciscis, Pasquale Sangiovanni, Angelo Della Corte, Luigi J Pers Med Systematic Review Radiation therapy (RT) is the standard of care in patients with locoregional or isolated vaginal recurrence who never underwent irradiation. It is often associated with brachytherapy (BT), whereas chemotherapy (CT) is a rare treatment option. We systematically searched the PubMed and Scopus databases in February 2023. We included patients with relapsed endometrial cancer, describing the treatment of locoregional recurrence, and reporting at least one outcome of interest—disease-free survival (DFS), overall survival (OS), recurrence rate (RR), site of recurrence, and major complications. A total of 15 studies fulfilled the inclusion criteria. Overall, 11 evaluated RT only, 3 evaluated CT, and 1 analyzed oncological outcomes after administration with a combination of CT and RT. In total, 4.5-year OS ranged from 16% to 96%, and DFS ranged from 36.3% to 100% at 4.5 years. RR ranged from 3.7% to 98.2% during a median follow-up of 51.5 months. Overall, RT showed a 4.5-year DFS from 40% to 100%. CT revealed 36.3% DFS at 4.5 years. RT showed a 4.5-year OS ranging from 16% to 96%, whereas CT revealed a 27.7% OS rate. It would be appropriate to test multi-modality regimens to evaluate outcomes and toxicity. EBRT and BT are the most employed options to treat vaginal recurrences. MDPI 2023-05-24 /pmc/articles/PMC10304022/ /pubmed/37373875 http://dx.doi.org/10.3390/jpm13060886 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Systematic Review Ronsini, Carlo Iavarone, Irene Reino, Antonella Vastarella, Maria Giovanna De Franciscis, Pasquale Sangiovanni, Angelo Della Corte, Luigi Radiotherapy and Chemotherapy Features in the Treatment for Locoregional Recurrence of Endometrial Cancer: A Systematic Review |
title | Radiotherapy and Chemotherapy Features in the Treatment for Locoregional Recurrence of Endometrial Cancer: A Systematic Review |
title_full | Radiotherapy and Chemotherapy Features in the Treatment for Locoregional Recurrence of Endometrial Cancer: A Systematic Review |
title_fullStr | Radiotherapy and Chemotherapy Features in the Treatment for Locoregional Recurrence of Endometrial Cancer: A Systematic Review |
title_full_unstemmed | Radiotherapy and Chemotherapy Features in the Treatment for Locoregional Recurrence of Endometrial Cancer: A Systematic Review |
title_short | Radiotherapy and Chemotherapy Features in the Treatment for Locoregional Recurrence of Endometrial Cancer: A Systematic Review |
title_sort | radiotherapy and chemotherapy features in the treatment for locoregional recurrence of endometrial cancer: a systematic review |
topic | Systematic Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10304022/ https://www.ncbi.nlm.nih.gov/pubmed/37373875 http://dx.doi.org/10.3390/jpm13060886 |
work_keys_str_mv | AT ronsinicarlo radiotherapyandchemotherapyfeaturesinthetreatmentforlocoregionalrecurrenceofendometrialcancerasystematicreview AT iavaroneirene radiotherapyandchemotherapyfeaturesinthetreatmentforlocoregionalrecurrenceofendometrialcancerasystematicreview AT reinoantonella radiotherapyandchemotherapyfeaturesinthetreatmentforlocoregionalrecurrenceofendometrialcancerasystematicreview AT vastarellamariagiovanna radiotherapyandchemotherapyfeaturesinthetreatmentforlocoregionalrecurrenceofendometrialcancerasystematicreview AT defranciscispasquale radiotherapyandchemotherapyfeaturesinthetreatmentforlocoregionalrecurrenceofendometrialcancerasystematicreview AT sangiovanniangelo radiotherapyandchemotherapyfeaturesinthetreatmentforlocoregionalrecurrenceofendometrialcancerasystematicreview AT dellacorteluigi radiotherapyandchemotherapyfeaturesinthetreatmentforlocoregionalrecurrenceofendometrialcancerasystematicreview |